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We document the second known case of Cache Valley
virus disease in a human. Cache Valley virus disease is
rarely diagnosed in North America, in part because labora-
tories rarely test for it. Its true incidence, effect on public
health, and full clinical spectrum remain to be determined.
C
ache Valley virus (CVV), a mosquitoborne member of
the Bunyamwera serogroup, family Bunyaviridae,
genus Orthobunyavirus, is geographically widespread in
North America, where it circulates between mosquitoes
and mammals (1). It has previously been associated with
only a single case of human disease, a fatal case of acute
encephalitis in the southeastern United States (2). We
describe the second documented human case of CVV
disease.
Case Report
In late October 2003, a 41-year-old, generally healthy
Wisconsin man, who lived near a landfill in the suburbs of
a small city on the Lake Michigan shore, became acutely
ill with severe headache, nausea, vomiting, and fatigue.
The next day, he was hospitalized with a diagnosis of acute
aseptic meningitis. On admission, his body temperature
was 38.4°C (101.1°F); no neck stiffness, rash, or focal neu-
rologic abnormalities were detected. Computerized tomo-
graphic and magnetic resonance imaging scans of the brain
were normal. The peripheral leukocyte count was
13,900/mm3, with 87% neutrophils and 7% lymphocytes.
Cerebrospinal fluid (CSF) examination showed 865 leuko-
cytes/mm3, with 73% lymphocytes, 15% monocytes, 12%
neutrophils, and no erythrocytes; a protein concentration
of 105 mg/dL, (normal 15–45 mg/dL); a glucose concen-
tration of 47 mg/dL(normal 50–80 mg/dL); negative Gram
stain; negative latex agglutination test results for antigens
of Neisseria meningitidis groups A, B, C, Y, and W135,
Haemophilus influenzae type b, Streptococcus pneumoni-
ae,  Escherichia coli K1, and group B streptococci
(Directigen Meningitis Combo Test Kit, BD, Franklin
Lakes, NJ, USA); and negative routine bacterial cultures.
Empiric intravenous antimicrobial drugs and corticos-
teroids were begun, and pain medications were adminis-
tered. After 3 days, the patient’s condition improved, and
he was discharged on a tapering course of oral corticos-
teroids. Four months later, he reported feeling fully recov-
ered except for experiencing headaches more frequently
than usual.
After the patient’s hospital discharge, the Wisconsin
State Laboratory of Hygiene isolated a virus (designated
strain WI-03BS7669) from an acute-phase CSF specimen.
This isolate caused extensive cytopathic effects (CPE) in
A549 (human lung adenocarcinoma) cells by 3 days after
infection and in RD (human embryonal rhabdomyosarco-
ma) cells by 6 days, but no CPE were seen in primary mon-
key kidney or WI-38 (human embryonic lung) cells.
Fluorescent-antibody test results of cell culture material
were negative for adenoviruses, cytomegalovirus, varicel-
la-zoster virus, herpes simplex virus, and enteroviruses,
and polymerase chain reaction (PCR) assays for
enteroviruses were negative. When electron microscopy of
culture material showed virions morphologically similar to
bunyaviruses, the isolate was sent to the Arboviral
Diseases Branch of the Centers for Disease Control and
Prevention (CDC) for characterization. By using primers
targeted to a highly conserved 251-base portion of the
smallest of the 3 RNA segments (RNA-S) of members of
the Bunyamwera and California serogroups of the family
Bunyaviridae, strain WI-03BS7669 was shown by PCR to
share considerable homology with members of these
serogroups (3). Subsequent nucleotide sequencing of
≈84% of RNA-S (795 of 950 total nucleotides in genome
positions 84–878, GenBank accession no. DQ315775) fol-
lowed by a BLAST (Basic Local Alignment Search Tool)
search in GenBank showed that strain WI-03BS7669 was
99% identical to prototype CVV strain 6V633 (GenBank
accession no. X73465; R.M. Elliott, pers. comm.) but only
90% identical to several other Bunyamwera serogroup
viruses, including Potosi, Northway, Maguari, and
Bunyamwera (4). In addition, a 694-base fragment ampli-
fied from the RNA-M segment of WI-03BS7669, followed
by nucleic acid sequence analysis and a BLAST search,
showed 98% sequence identity with 6 CVV strains but
only 77% identity with Maguari virus (4).
No acute-phase serum was available for arboviral sero-
logic testing. However, convalescent-phase serum collect-
ed from the patient 4 months after illness onset was
strongly positive (titer 1,280) for neutralizing antibody to
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Conclusions
The Bunyamwera serogroup includes ≈30 viruses, with
known representatives on every continent except
Antarctica (R. Weir, pers. comm.) (1,5,6). Transmission
cycles for these viruses have been little studied, but most
isolates have been from culicine and anopheline mosqui-
toes, and mammals are considered the primary amplifying
hosts. In Africa and Central and South America,
Bunyamwera serogroup viruses cause sporadic human ill-
ness, including undifferentiated febrile illness, fever with
exanthem, meningitis, and rarely, encephalitis. At least 7
different Bunyamwera serogroup viruses have been isolat-
ed from humans, usually from blood, including
Bunyamwera, Germiston, Ilesha, and Shokwe viruses in
Africa; Xingu virus in South America; Wyeomyia virus
and a Cache Valley–like virus in Central America; and
CVV in the southeastern United States (1,2,5,7,8). Ngari
virus, a reassortant bunyavirus with RNA segments from
both a Bunyamwera serogroup virus and an unidentified
member of the genus Orthobunyavirus, has recently been
associated with epidemic hemorrhagic fever in Africa (9).
CVV is 1 of at least 9 Bunyamwera serogroup viruses
in North America (1,5,6,10), where it was first isolated
from  Culiseta inornata mosquitoes collected in Cache
Valley, Utah, in 1956 (5). Although it has been isolated
from >20 different species of culicine or anopheline mos-
quitoes, most frequently from Anopheles quadrimaculatus
(1,5), the principal mosquito vectors are unknown. The
vertebrate amplifying hosts of CVV have been little stud-
ied, but a high prevalance of neutralizing antibody to this
virus is often found in ungulates, including deer, sheep,
horses, and cattle (5,10–12). The virus has been isolated
from a healthy cow and a sick sheep in Texas (13) and
from a healthy horse in Michigan (12). It is teratogenic in
sheep (14).
Previous serosurveys have indicated that humans in
some parts of the United States are commonly infected by
Bunyamwera serogroup viruses. For example, neutralizing
antibody to CVV was found in 12% of 356 persons sur-
veyed in Maryland and Virginia in the 1960s (15). Such
results, however, are often difficult to interpret because of
nonrandom sampling, multiple Bunyamwera serogroup
members circulating in the same area, inclusion of a limit-
ed number of viruses in tests, and serologic cross-reactivi-
ty among members of the serogroup.
Only 2 cases of human disease due to Bunyamwera
serogroup viruses were previously reported in temperate
North America. The first was an encephalitis case in
Indiana attributed to Tensaw virus in 1964 (5).
Unfortunately, because no details about this case or the
method of diagnosis were provided, and because the
known range of Tensaw virus does not include Indiana, the
validity of this report is uncertain. The second was a fatal,
culture-confirmed case of CVV encephalitis in a young
adult in North Carolina in 1995 (2).
Thus, our case of CVV meningitis is only the second
documented human case of CVV disease. This case appar-
ently lacked any unique clinical or routine laboratory fea-
tures, and the diagnosis of CVV disease was made by the
isolation of this virus from CSF by a state public health
reference laboratory. The viral genomic sequence data and
high-titer neutralizing antibody to CVV in the patient’s
convalescent-phase serum confirmed this case to be an
acute CVV infection. Few CSF specimens are cultured for
arboviruses because relatively few diagnostic laboratories
have the expertise to do so and because even in acute, sero-
logically confirmed cases of neuroinvasive arboviral dis-
ease, the isolation rate from CSF is generally low. No tests
for CVV immunoglobulin M, such as enzyme immunoas-
say, are available. Tests for neutralizing antibody to this
virus require handling live virus under biosafety level 2
containment and thus are only available by special request
at CDC (through state health departments) and selected
reference laboratories. In conclusion, CVV disease is a
neuroinvasive illness rarely diagnosed in North America,
in part because laboratories rarely test for it. Its true inci-
dence, effect on public health, and full clinical spectrum
remain to be determined.
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